GeneDx Holdings EBIT

The latest EBIT for SMFR is $-82M as of June 2026. That compares with $5.4M in the prior-year period — down 1604.2% year over year. That is below the Healthcare sector average of $130B. Investors often review this figure alongside GeneDx Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, SMFR's EBIT moved from $5.4M to $-82M — a 1604.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in GeneDx Holdings's operating scale or balance-sheet position.

Against Healthcare companies, SMFR currently prints $-82M for EBIT, while the sector average sits near $130B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at GeneDx Holdings's growth, margins, and balance sheet.

A EBIT figure of $-82M for SMFR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $130B. Explore the charts below for those layers of context.

After noting SMFR's EBIT ($-82M), review year-over-year change from $5.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.